Search
Inolimomab
go.drugbank.com/drugs/DB15628InvestigationalInolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. … It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385]
FG-2216
go.drugbank.com/drugs/DB08687InvestigationalA orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability. [A14422]
Synonyms: 1-Chloro-N- (hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide, 1-Chloro-N-(hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamidePM02734
go.drugbank.com/drugs/DB05158InvestigationalPM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.
Probiorinse
go.drugbank.com/drugs/DB15870ExperimentalProbiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136. … [L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193]
Saposin C
go.drugbank.com/drugs/DB17380InvestigationalSaposin C is a lysosomal protein. Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy. … BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.
SynOV1.1
go.drugbank.com/drugs/DB17539InvestigationalSynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).